Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ).
Shanghai Bio-heart Biological Technology Co., Ltd. announced that its Joint Company Secretary, Mr. Yunqing Wang, has been confirmed by the Hong Kong Stock Exchange as qualified to independently fulfill his secretarial duties after the expiry of the initial waiver period. Despite a slight delay in the confirmation process, the company assured stakeholders of Mr. Wang’s capabilities and continued support from Ms. Kwok, highlighting its commitment to maintaining high corporate governance standards.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. operates in the biotechnology industry and is incorporated in the People’s Republic of China. The company is involved in the development and commercialization of biological technology products and services, focusing on innovations and compliance with regulatory standards.
YTD Price Performance: -8.54%
Average Trading Volume: 26,992
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$627.8M
For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.
